State Street Corp Lowers Stake in Daré Bioscience, Inc. (NASDAQ:DARE)

State Street Corp reduced its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 91.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,515 shares of the biotechnology company’s stock after selling 258,695 shares during the quarter. State Street Corp owned approximately 0.28% of Daré Bioscience worth $76,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Renaissance Technologies LLC lifted its position in shares of Daré Bioscience by 2.1% in the second quarter. Renaissance Technologies LLC now owns 778,700 shares of the biotechnology company’s stock valued at $262,000 after acquiring an additional 15,800 shares in the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

Daré Bioscience Stock Performance

DARE opened at $3.37 on Friday. The stock has a market capitalization of $29.32 million, a price-to-earnings ratio of -5.71 and a beta of 1.28. The company has a fifty day moving average of $3.45 and a 200 day moving average of $3.53. Daré Bioscience, Inc. has a fifty-two week low of $2.67 and a fifty-two week high of $7.56.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Daré Bioscience in a research report on Tuesday, December 17th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.